E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10019828 |
E.1.2 | Term | Hepatocellular carcinoma non-resectable |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to compare overall survival (OS) for ramucirumab versus placebo in patients with advanced HCC after intolerance or progression on prior sorafenib treatment
|
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of the study are to evaluate:
• Progression-free survival (PFS)
• Time to radiographic progression (TTP)
• Objective response rate (ORR)
• Safety profile of ramucirumab
• Ramucirumab pharmacokinetics (PK)
• Immunogenicity of ramucirumab
• Patient-reported outcome (PRO) measures of disease-specific symptoms and health related quality of life
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
[1] The patient has a diagnosis of HCC based on either:
a. histopathologic or cytologic findings
b. in the absence of histologic confirmation, a diagnosis of cirrhosis and HCC with classical imaging characteristics (that is, at least a 3-phase liver protocol CT or MRI and a lesion that demonstrates arterial hyperenhancement and washes out in the venous phase).
[2] The patient received sorafenib treatment for at least 14 days and discontinued sorafenib treatment 14 days prior to randomization.
[3] The patient experienced radiographically confirmed disease progression during or after discontinuation of sorafenib therapy or discontinued sorafenib treatment because of intolerance despite appropriate sorafenib management and supportive care.
[4] The patient received sorafenib as the only systemic therapeutic intervention for advanced HCC.
[5] The patient has 1 measurable lesion per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 (Eisenhauer et al. 2009) that has not been previously treated with locoregional therapy.
[6] The patient is 18 years of age or of an age acceptable according to local regulations, whichever is older.
[7] The patient has a Child-Pugh score of <7 (Child-Pugh Class A only).
[8] The patient has Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy.
[9] The patient has a baseline AFP 400 ng/mL, as determined by local laboratory testing.
|
|
E.4 | Principal exclusion criteria |
[17] The patient has fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma.
[18] The patient had a previous or has concurrent malignancy. Patients with carcinoma in situ of any origin and patients with prior malignancies who are in remission and whose likelihood of recurrence is very low, as judged by the investigator, may be eligible for this study in consultation with and approval by the Lilly CRP.
[19] The patient has previously documented brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression.
[20] The patient has a history of or current hepatic encephalopathy (any grade) or clinically meaningful ascites. Clinically meaningful ascites is defined as CTCAE Grade >1 ascites resulting from cirrhosis. Patients who have been on a stable medical regimen (for 3 months) to manage ascites are eligible if they show no evidence of ascites on clinical exam that would require further intervention.
[21] The patient has ongoing or recent (6 months prior to randomization) hepatorenal syndrome.
[22] The patient had a prior liver transplant.
[23] The patient received any previous systemic therapy with VEGF inhibitors or VEGF-Receptor inhibitors (including investigational agents) other than sorafenib for treatment of HCC.
[24] The patient received any hepatic locoregional therapy (including radiation, surgery, hepatic arterial embolization, chemoembolization, radiofrequency ablation, cryoablation, or percutaneous ethanol injection) following sorafenib or within 28 days prior to randomization. Use of locoregional therapy prior to sorafenib is allowed.
[25] The patient received radiation to any nonhepatic (for example, bone) site within 14 days prior to randomization. Prior radiation to >25% total bone marrow is not allowed.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Compare ramucirumab versus placebo in terms of OS in patients with advanced HCC after intolerance or progression on prior sorafenib |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary analysis will be performed after approximately 318 deaths have been observed |
|
E.5.2 | Secondary end point(s) |
The secondary objectives of the study are to evaluate: progression-free survival, time to radiographic progression, objective response rate (ORR), safety profile of ramucirumab, ramucirumab pharmacokinetics, immunogenicity of ramucirumab, and patient-reported outcome measures of disease-specific symptoms and health-related quality of life. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary endpoints will be analyzed at the same time as OS and at the same level of significance.
2 safety interim analyses are planned to be performed when approximately 50 and 150 patients have received 3 cycles of study treatment, died, or discontinued study treatment. Thereafter, safety review will be conducted twice annually, or as requested by the IDMC
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Immunogenicity, Health Outcome |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 51 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Austria |
Belgium |
Brazil |
Canada |
China |
Czech Republic |
France |
Germany |
Hong Kong |
Israel |
Italy |
Japan |
Korea, Republic of |
Poland |
Spain |
Switzerland |
Taiwan |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 0 |